SCHEMBL5162818

SCHEMBL5162818

N#CCC(O)c1ccc(Cl)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.40
CYP2D6 P10635 3/20 0.40
SLC6A2 P23975 3/20 0.40
SLC6A4 P31645 3/20 0.40
SLC6A3 Q01959 3/20 0.40
KCNH2 Q12809 1/20 0.37
S1PR3 Q99500 1/20 0.35
NAPRT Q6XQN6 1/20 0.34
ADRB1 P08588 2/20 0.33
ADRB3 P13945 2/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
MEN1 O00255 1/20 0.33
CHRNA7 P36544 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
DGAT1 O75907 1/20 0.33
ADRA2A P08913 2/20 0.33
ADRA2B P18089 2/20 0.33
ADRA2C P18825 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1983382 0.80 CYP3A4 (0.44) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL169697 0.79 SMN1; SMN2 (0.36) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL19062270 0.79 CYP3A4 (0.34) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL6334139 0.78 CYP3A4 (0.43) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL6426357 0.78 CYP3A4 (0.43) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL6541805 0.78 CYP3A4 (0.43) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL12251237 0.77 CYP3A4 (0.36) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL8689386 0.77 CYP3A4 (0.42) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL8924164 0.77 LMNA (0.45) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL22230007 0.76 L3MBTL1 (0.39) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
CN-1168721-C 5-cyano-2-aminopyrimidine derivatives О 2004-09-29 CN disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed
CN-1370152-A 5-cyano-2-aminopyrimidine derivatives CELLETECH CHIROSCIENCE LTD (GB) 2002-09-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO CYP3A4 7/4885CYP2D6 86/4885SLC6A2 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.